Highlights Eyenovia, Inc.

Equities

EYEN

US30234E1047

Real-time Estimate Cboe BZX Other stock markets 12:51:18 2024-04-30 pm EDT			5-day change	1st Jan Change
0.773 ^USD	+8.54%		+43.70%	-62.51%

Apr. 25	Eyenovia Provides Clinical and Scientific Update on FDA-Approved Products Mydcombi and Clobetasol Propionate Ophthalmic Suspension	CI
Apr. 08	Eyenovia to Weigh Potential Sale, Other Strategic Alternatives	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Eyenovia Provides Clinical and Scientific Update on FDA-Approved Products Mydcombi and Clobetasol Propionate Ophthalmic Suspension	Apr. 25	CI
Eyenovia to Weigh Potential Sale, Other Strategic Alternatives	Apr. 08	MT
Eyenovia, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 18	CI
NovaBay Pharmaceuticals and Eyenovia to Co-Promote Prescription Ophthalmic Products to U.S. Eyecare Professionals	Mar. 13	CI
Eyenovia Reports FDA Approval for Formosa's Post-Op Eye Inflammation, Pain Treatment	Mar. 05	MT
US FDA approves Eyenovia's eye drug, Formosa Pharma says	Mar. 04	RE
Eyenovia, Inc Announces FDA Approval of Redwood City as Commercial Manufacturing Facility	Feb. 13	CI
Eyenovia, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13	CI
Eyenovia, Inc. Announces Fda Approval of Coastline International as Contract Manufacturer to Initiate Mydcombi Commercial Production	Nov. 02	CI
Eyenovia Acquires US Rights to Eye Surgery Drug From Formosa	23-08-16	MT
Formosa Pharmaceuticals Announces Licensing Agreement with Eyenovia, Inc., for the Commercialization of App13007 for the Treatment of Inflammation and Pain Following Ocular Surgery	23-08-16	CI
Eyenovia, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10	CI
Eyenovia, Inc. Announces First Commercial Sale of Mydcombi	23-08-03	CI
Eyenovia, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-11	CI
US FDA approves Eyenovia's pupil-dilating spray	23-05-08	RE
US FDA approves Eyenovia's pupil-dilating spray	23-05-08	RE
Eyenovia, Inc. Announces FDA Approval of Mydcombi, the First Ophthalmic Spray for Mydriasis	23-05-08	CI
Eyenovia, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022	23-03-30	CI
Eyenovia Signs Ophthalmic Collaboration Deal With Formosa Pharmaceuticals; Shares Rise	23-02-15	MT
Formosa Pharmaceuticals, Inc. Enter into A Collaboration Agreement with Eyenovia, Inc. for the Development of Novel Ophthalmic Therapeutics	23-02-15	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Eyenovia, Inc.

Equities

EYEN

US30234E1047

Highlights

Filters